tbuckley/cabot-search huggingface dataset:
The antitumor effects of CIK cells combined with docetaxel against drug-resistant lung adenocarcinoma cell line SPC-A1/DTX in vitro and in vivo
Authors: L. Pengying, C. Longbang, H. Xiang
Journal: Journal of Clinical Oncology (2009)

3039 Background: Cytokine-induced killer (CIK) cells transfer is now being considered the most promising adoptive cellular therapy strategy. Multidrug resistance (MDR) phenomenon is a major hindrance to the successful chemotherapy of cancer. In this study, the anti-tumor activity of CIK cells combined with docetaxel (DTX) against multidrug resistance SPC-A1/DTX cell line was evaluated in vitro and in vivo. Methods: MTT assay was employed to evaluate the cytotoxic activity of DTX, CIK cells, and DTX plused CIK cells against SPC-A1/DTX cells in vitro. In vivo assay, SPC-A1/DTX cells were injected to nude mice subcutaneously to establish tumor-bearing mice model. On the 14th day, normal saline, docetaxel, CIK cells, and CIK cells combined with docetaxel were administered intraperitoneally respectively. All the nude mice were sacrificed at day 15 after treatment and the tumor were weight out. Results: MTT assay showed that CIK cells possessed a higher antitumor cytotoxic activity against SPC-A1/DTX cells than SPC-A1 cells in vitro (p &lt;0.05). The synergetic anti-tumor activity positively correlated with the E:T ratio and the concertration of docetaxel. The animal data also suggested that CIK cells combined with DTX had a stronger suppressive effect on the tumor growth in vivo. Conclusions: CIK cells plused with docetaxel demonstrated a prominent augmentation of anti-tumor activity against MDR lung adenocarcinoma cell lines both in vitro and in vivo. No significant financial relationships to disclose.
A specifically designed nanoconstruct associates, internalizes, traffics in cardiovascular cells, and accumulates in failing myocardium: a new strategy for heart failure diagnostics and therapeutics
Authors: Guillermo U. Ruiz‐Esparza, Victor Segura‐Ibarra, Andrea M. Cordero‐Reyes, Keith A. Youker, Rita E. Serda, Ana S. Cruz‐Solbes, Javier Amione‐Guerra, Kenji Yokoi, Dickson K. Kirui, Francisca E. Cara, Jesus Paez‐Mayorga, Jose H. Flores‐Arredondo, Carlos E. Guerrero‐Beltrán, Gerardo Garcia‐Rivas, Mauro Ferrari, Elvin Blanco, Guillermo Torre‐Amione
Journal: European Journal of Heart Failure (2016)
Lethal Midline Granuloma Revisited: Nasal T/Natural-Killer Cell Lymphoma
Authors: C. S. Chim, G. C. Ooi, T. W.H. Shek, R. Liang, Y. L. Kwong
Journal: Journal of Clinical Oncology (1999)

Article Tools DIAGNOSIS IN ONCOLOGY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1999.17.4.1322 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 10561195 Lethal Midline Granuloma Revisited: Nasal T/Natural-Killer Cell Lymphoma C. S. ChimxC. S. ChimSearch for articles by this author , G. C. OoixG. C. OoiSearch for articles by this author , T. W.H. ShekxT. W.H. ShekSearch for articles by this author , R. LiangxR. LiangSearch for articles by this author , Y. L. KwongxY. L. KwongSearch for articles by this author Show More Queen Mary Hospital, University of Hong Kong, Hong Kong https://doi.org/10.1200/JCO.1999.17.4.1322 First Page Full Text PDF Figures and Tables © 1999 by American Society of Clinical Oncology
Discharge delays reach eight year high as social care budgets are squeezed
Authors: Zosia Kmietowicz
Journal: BMJ (2015)

Cuts to social care budgets are adversely affecting health services, and delays in discharge from hospital are at their highest since 2007, says a report from the health think tank the King’s Fund.

Nearly nine in 10 (88%) NHS trust finance directors and 80% of finance leads in clinical commissioning groups who responded to a survey from the King’s Fund thought that funding pressures on local authorities had negatively affected performance of health services in their area.

Altogether 90 trust finance directors (37% of those contacted) and 50 CCG finance leads (27%) responded to the survey, which was carried out …
Benefits of preoperative chemotherapy for operable breast cancer in the community hospital setting
Authors: I. K. Komenaka, M. L. Hibbard, M. E. Bouton
Journal: Journal of Clinical Oncology (2009)

e11594 Background: The benefits of preoperative chemotherapy (PC) for operable breast cancer have been demonstrated in prospective clinical trials. For palpable breast cancers, however, operative intervention remains the most common initial treatment. The benefits of PC for operable breast cancer were examined in a community hospital. Methods: Maricopa Medical Center is the safety net hospital in Arizona. A retrospective review was performed of all breast cancer patients from 2004 to 2008. All patients who were stage IIA - IIIA breast cancer patients were included. Outcomes of breast cancer were evaluated based on whether the patient underwent PC or adjuvant chemotherapy (AC). All patients in the PC group received anthracyclines and a taxane in their treatment. The Fisher's exact test and the Chi-square test were used to determine differences between the two populations. Unpaired t-test was used to compare means of the two populations. Results: During this period, 145 patients were treated. In the PC group, the clinical response rate was 81% and the pathologic complete response rate was 26%. Patients in the PC group underwent lumpectomy more often for T2 (73% vs. 40%, P = 0.01) and for T3 tumors (73% vs. 37%, P = 0.06). The positive margin rate was lower (14% vs.37%, P = 0.02) and the lumpectomy volume was smaller in the PC group compared to the AC group (132 cm3 vs. 245 cm3, P &lt; 0.01). Despite similar demographics, compliance with chemotherapy was improved in the PC group (100% vs. 71%, P &lt; 0.01). In addition, compliance was also improved for adjuvant radiation (97% vs. 70%, P &lt; 0.01) and hormone therapy (100% vs. 76%, P = 0.01) in the PC group. Conclusions: Preoperative chemotherapy improved compliance with chemotherapy. This could represent a significant benefit over AC in populations where compliance with chemotherapy recommendations is not ideal. Improvements in surgical outcomes were also seen in patients who received preoperative chemotherapy in the community hospital setting. No significant financial relationships to disclose.
Induction chemotherapy and following simultaneous radiochemotherapy versus induction chemotherapy and radiotherapy alone in inoperable NSCLC (Stage IIIA/IIIB): Update of CT/RT 99/97
Authors: R. M. Huber, M. Flentje, H. Gosse, B. Poellinger, M. Schmidt, J. Willner, K. Ulm
Journal: Journal of Clinical Oncology (2004)

7075 Background: In NSCLC simultaneous or induction radiochemotherapy is superior to chemo- or radiotherapy alone. Our study proves, weather after induction chemotherapy simultaneous radiochemotherapy is superior to radiotherapy alone. Methods: Patients (pts) with inoperable NSCLC IIIA/B are included. They get 2 cycles q3w of Paclitaxel 200mg/m2 and Carboplatinum AUC 6. If the tumor is not progressive the pts are randomized to radiotherapy alone (total dose at least 60 Gy per fraction) or simultaneous chemotherapy with weekly Paclitaxel 60mg/m2 and the same radiotherapy. Primary objective is survival; secondary endpoints are time to progression, response and toxicity. Results: Inclusion ended 05/02. The last follow-up was 11/03. As planned, 303 pts are included in the trial. 275 pts finished induction-therapy. 219 pts could be randomized: radiotherapy 115 pts, simultaneous radiochemotherapy 104 pts. Median survival is higher in the simultaneous arm: 18.67 months (95%CI 14.05–23.29) versus 14.1 months (95%CI 11.64–16.56). Progression free survival is statistically superior (log rank: p=0.0003) in the simultaneous arm: median 11.43 months (95%CI 7.88–14.98) versus 5.57 months (95%CI 3.88–7.25). In the simultaneous arm there are also statistically less recurrences (Pearson Chi-Square: p<0.001): 62.1% vs. 83.8%. The reduction on recurrences can be seen in local as in distant relapses. Toxicities are not statistically different. Conclusions: The combination of induction chemotherapy and then simultaneous radiochemotherapy with weekly Paclitaxel is superior to induction alone regarding progression-free survival, without increased toxicities. Also the survival seems to be better (not yet statistically significant). Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Bristol-Myers Squibb Germany Bristol-Myers Squibb
Demographic and Epidemiological Characteristic of Egfr Mutation and Alk Gene Rearrangement Among Indian Patients with Lung Adenocarcinoma
Authors: D.C. Doval, K. Prabhash, S. Patil, H. Chaturvedi, C. Goswami, A.K. Vaid, S. Desai, S. Dutt, V.H. Veldore, N. Jambhekar, A. Mehta, D. Hazarika, S. Azam, S. Gupta, S. Gawande
Journal: Annals of Oncology (2014)
Phase I study of capecitabine in combination with CPT-11 for metastatic breast cancer (MBC) pre-treated with anthracycline and taxanes
Authors: M. Kashiwaba
Journal: Journal of Clinical Oncology (2008)

1123 Background: Capecitabine (Cap) has been administrated with other drugs to improve the response rate of single agent and to extend time to progression for MBC expecting synergistic effect such as up-regulation of thymidine phosphorylase activity. Conversely, administration of CPT-11 (CPT) against MBC is not common while some studies showed certain efficacy using single, or combination therapies. We designed to determine maximum tolerated dose (MTD) and recommended dose (RD) of CPT (80, 90, 100, 110 and 120 mg/m2) on Day 1 and 15 and Cap (1,657 mg/m2/day) on Day 1–21 against MBC pre-treated with anthracycline and taxanes. Methods: A standard “3+3” design is utilized and DLT was defined during the first cycle as any grade 3/4 or delay >3 weeks due to toxicity. Results: 12 pts were enrolled, the mean age was 53y, no pts were experienced grade 3–4 toxicities in 3 pts of level I (TOP: 80 mg/m2), 3 pts of level II (TOP: 90mg/m2), but another 3 pts were enrolled because one grade 3 diarrhea was observer in 1pt out of 3 pts in level III (TOP: 100 mg/m2). Finally 3 pt had grade 3 photophobia, fatigue, diarrhea as DLTs in level III out of 6 pts, TOP: 100 mg/m2 was decided as MTD and RD was established at TOP: 90 mg/m2 on Day 1 and 15 and Cap (1,657 mg/m2/day) on Day 1–21. 5 of 12 pts (41.7%) had an investigator-assessed partial response by RECIST. Conclusions: Combination therapy C and TOP against MBC pre-treated anthracycline and taxane is well-tolerated at the dose and schedule currently evaluated with better response rate than single agent of Cap. Multicenter phase II study will be prepared to confirm efficacy with pharmacokinetic assessment. No significant financial relationships to disclose.
Phylogeny of protostome worms derived from 18S rRNA sequences.
Authors: B Winnepenninckx, T Backeljau, R De Wachter
Journal: Molecular Biology and Evolution (1995)

The phylogenetic relationships of protostome worms were studied by comparing new complete 18S rRNA sequences of Vestimentifera, Pogonophora, Sipuncula, Echiura, Nemertea, and Annelida with existing 18S rRNA sequences of Mollusca, Arthropoda, Chordata, and Platyhelminthes. Phylogenetic trees were inferred via neighbor-joining and maximum parsimony analyses. These suggest that (1) Sipuncula and Echiura are not sister groups; (2) Nemertea are protostomes; (3) Vestimentifera and Pogonophora are protostomes that have a common ancestor with Echiura; and (4) Vestimentifera and Pogonophora are a monophyletic clade.
Joint modeling, quality of life, and survival in fast-track (or delayed-start) palliative care trials.
Authors: Zhigang Li, H.R. Frost, Qian Yang, Marie Bakitas, Tor Tosteson
Journal: Journal of Clinical Oncology (2014)

49 Background: Randomized “early intervention” or “fast-track” trials (also sometimes called delayed intervention, delayed-start, or wait list designs) have been proposed as an alternative to traditional RCTs comparing palliative care interventions to non-palliative or other supportive care groups. The fast-track arm receives intervention immediately after randomization and the control arm receiving intervention after a certain period following randomization during which time standard care is provided. Such trials are more acceptable to patients, families and physicians because no one is denied access to the intervention, while still allowing for a rigorous assessment of a palliative care intervention. Many issues remain with respect to implementing such designs and analyzing the longitudinal quality of life and survival. Methods: We have developed a terminal decline model (Li et al. 2013) for jointly modeling quality of life and survival in palliative care studies. This model can be implemented on an intention to treat basis for the overall comparison in fast track design. For time periods beyond the delayed start period, we modify the model to include a time-varying treatment variable in the model to account for the treatment change in the control arm, including an interaction between the treatment and the time period. Terminal declines and quality-adjusted life years are estimated for both the intention to treat and the modified model. Results: ENABLE III is a recently completed fast-track trial in our institution at Dartmouth. After applied to ENABLE III study, the novel statistical joint modeling approach indicates that the effect of the ENABLE intervention on the terminal decline increases when combined with intervention effect seen for fast track arm. Conclusions: The terminal decline joint modeling approach is an efficient and interpretable method for fast-track study designs.
Antitumor effect of dendritic cell-based cancer vaccine in combination with chemotherapy in patients with advanced colorectal cancer.
Authors: M. Okamoto, S. Akiyama, T. Tomoda, H. Abe, J. Tsukada
Journal: Journal of Clinical Oncology (2010)

e13103 Background: Tumor-specific cytotoxic T lymphocytes (CTLs) can be activated in vivo by dendritic cell (DC)- based vaccination. However, clinical responses to the immunotherapy with DC vaccination have only been observed in a minority of patients with solid cancer. Combination with other treatment modalities such as chemotherapy may overcome immunoresistance of cancer cells. In the current study, the clinical efficacy of the DC vaccine pulsed with the peptide derived from colorectal cancer-associated antigens in combination with chemotherapy has been evaluated in patients with advanced, inoperable colorectal cancer. Methods: Thirty-two patients with advanced, inoperable colorectal cancer refractory to standard treatment were entered into the study. DCs that were generated from CD14+ monocytes from leukapheresis by 6-day cultivation with granulocyte macrophage-colony stimulating factor (GM-CSF) and interleukin (IL)-4, were matured by OK-432, a streptococcal agent, and were pulsed with the pancreatic cancer-associated antigens, such as WT1, MUC1. These DCs (1 × 107) were intradermally administered 5 times at 14- day intervals. Results: Of the 32 patients, complete response (CR) was observed in 0 (0%), partial response (PR) in 7 (21.9%), stable disease (SD) in 12 (37.5%), progressive disease (PD) in 13 (40.6%). Response rate was 21.9%. Tumor control rate was 59.4%. Survival rate, quality of life, performance status were markedly increased. Severe side effects of more than grade 3 which were assessed in accordance with NCI-Common Toxicity Criteria v.2.0, were not observed. Conclusions: It was strongly suggested that the DC vaccination pulsed with cancer-associated peptides in combination with chemotherapy was safe and effective in patients with inoperable colorectal cancer refractory to standard treatment. No significant financial relationships to disclose.
Interobserver variability of size and density measurements on CT in patients with metastatic GISTS on imatinib mesylate (IM)
Authors: V. R. Bulusu, S. Fawcett, P. Moyle, N. Carroll
Journal: Journal of Clinical Oncology (2008)

10563 Background: Response assessment to IM in GISTs by Choi criteria depends on size/density measurements. These may be subject to interobserver variability. We evaluated the interobserver variability of size (longest dimension in mm) and density (mean Hounsfield units HFU) in patients (pts) with metastatic GISTs on IM. Methods: 27 lesions (Primary=3, Liver=7, Peritoneal=17) from 8 GIST pts on IM were included in the study. Contrast triple phase CT (Siemens multi slice CT, IV Niopam, GE PACS system) was performed at baseline and at 3 monthly intervals. In 2007, the authors (VRB, NC, SF & PM) evaluated the longest dimension and the mean density in HFU of all lesions and reached a consensus value for each lesion at baseline and at 3 months on IM. VRB and SF repeated the exercise independently in 2008. The values for longest dimension and mean density at baseline and at 3 months on IM were compared with the consensus dataset recorded earlier by the authors. Results: 2 datasets generated by VRB & SF were evaluated against the consensus dataset from 2007. At baseline, 81% of the values for size and 88% of the values for density (as measured by VRB & SF) were within 10% of the consensus values. At 3 months, these figures were 92% for size and 81% for density. Conclusions: We believe that both size and density measurements are reproducible and the interobserver variation seems to be acceptable. However, we recommend that these evaluations are carried out by radiologists with experience in assessing response to targeted therapy. No significant financial relationships to disclose.
Abstract 12540: Prognostic Significance and Determinants of the 6-Minute Walk Test in Patients With Heart Failure and Preserved Ejection Fraction
Authors: Caroline Tufaro, Julia Mascherbauer, Franz Duca, Benedikt Koell, Stefan Aschauer, Andreas Kammerlander, Adelheid Panzenboeck, Daniela Laimer, Robin Ristl, Irene Lang, Diana Bonderman
Journal: Circulation (2014)

Introduction:  Symptoms of exertional fatigue and dyspnea, as well as a reduced exercise tolerance are cardinal features of pulmonary hypertension (PH) associated with heart failure with preserved ejection fraction (HFpEF). The aim of the present study was to define the prognostic significance and clinical determinants of the six-minute walking distance (6-MWD) in affected patients.   Methods:  Consecutive patients with a definite diagnosis of PH-HFpEF, as confirmed by right heart catheter, were enrolled in our prospective, observational registry. Hospitalization for HF and/or death for cardiac reason were defined as the primary study endpoint. To establish determinants of the 6-MWD, 4 separate multiple regression models were constructed for TTE, hemodynamic, laboratory and pulmonary parameters. For quantification of left ventricular (LV) extracellular matrix (ECM) using the TissueFAXS software, myocardial biopsies were taken from 18 patients.   Results:  Between December 2010 and July 2013, 142 PH-HFpEF patients (99 f/43 m, mean age 71±9 years) were included to the study. After a mean follow-up of 14.0±10.0 months (range 0.5-34.0 months), 43 patients (30.3%) reached the combined endpoint. Patients in the adverse outcome group had a significantly shorter 6-MWD (246.8±115.6m vs. 345±110.2m, P   Conclusion:  The limited exercise capacity in PH-HFpEF patients can be explained by a variety of cardiac and non-cardiac factors that contribute to increased ECM deposition in the LV and consecutive hemodynamic alterations.
Abstract 15399: Caveolae Specific Location of L-type Calcium Channels and Their Role in Atrial Calcium Cycling
Authors: Alexey V Glukhov, Marina Balycheva, Navneet Bhogal, Ivan Diakonov, Jose S Alonso-Mardones, Andrei Buzuk, Giuseppe Faggian, Julia Gorelik
Journal: Circulation (2014)

Introduction: Important differences in Ca2+ signaling occurred between ventricular and atrial cardiomyocytes has been attributed to the lack of a regular T-tubular system and distinct distribution of atrial L-type Ca2+ channels (LTCCs). In addition to critical subpopulation of LTCCs localized to dyadic junctions, extradyadic channels associated with district regions of surface membrane have been distinguished.

Hypothesis: Here, we hypothesise that a subpopulation of LTCCs housed in caveolae microdomains, could play an important role in modulation of Ca2+ signaling, particularly in cells lacking T-tubules such as atrial cardiomyocytes.

Methods: Scanning ion conductance, confocal, and electron microscopy were used to characterize membrane topography, caveolae and T-tubular network in adult rat atrial cardiomyocytes. Ca2+-sensitive fluorescent dye Fluo-4AM was used to monitor changes in [Ca2+]i. Super-resolution scanning patch-clamp was applied to identify distribution of functional LTCCs, before and after caveolae depletion by methyl-β-cyclodextrin (MβCD).

Results: MβCD abolished ~60% caveolae and significantly decreased occurrence of spontaneous calcium events (from 1.64±0.22 events/cell at baseline to 0.57±0.15 events/cell after MβCD treatment, P<0.001). At baseline, functional atrial LTCCs were found both in the T-tubules and in the crest areas of the sarcolemma with similar occurrence. While MβCD did not affect LTCCs occurrence in the T-tubules (29% vs. 33%, before and after MβCD treatment, NS), it completely abolished occurrence of LTCCs on the crest of sarcolemma (33% vs. 0% before and after MβCD treatment, P<0.001). No changes in cell topography and T-tubule openings were observed after MβCD treatment. Along with changes in LTCCs distribution, MβCD decreased response to both β1- (6.52±1.42 events/cell vs. 2.66±0.59 events/cell before and after MβCD, P<0.05) and β2-ARs stimulation (3.20±0.58 events/cell vs. 1.45±0.21 events/cell before and after MβCD, P<0.05).

Conclusions: Our results provide the first direct evidence of caveolae specific localization and regulation of functional LTCCs in atrial cardiomyocytes and suggest their possible role in the mechanism of unique atrial calcium cycling.
How to improve the hospital stay in the oncologic patients
Authors: K. Cagossi, A. Pietramaggiori, M. G. Russomanno, R. Cattabriga, D. Barbieri, L. Cavanna, A. Iop, F. Artioli
Journal: Journal of Clinical Oncology (2005)

8276 Background: The growth of the “patient-centred” approach to health care has highlighted the importance of quality communication practices. There is a common feel to provide a welcome and support to the cancer patients and their families who are faced with suffering resulting from oncologic diseases and to begin with a cultural aspect modulated on the gradual change in order to improve the patient’s daily routine. In this way the focus is also on the life and not only on the person. Methods: Formation of various groups including patient’s support groups comprising of ex patients and staff, some groups talking about personal experiences, creative arts and laboratory groups and psychotherapy to assist with carrying out the day to day life in hospital. In this way in the hospital structure there is a pleasant and familiar atmosphere. The admitted patients with cancer and their familiars were invited to participate to this experience. Results: From January 2002 to January 2003 150 cancer patients with their familiars entered this study. 120/150 patients (80%) showed a reduction of anxiety and depression and improved their relationship with the oncology unit; 94/150 patients (63%) had an improvement in the relationship with doctors, with staff and a reduction of the anxiety related to invasive procedures and chemotherapy. All the patients received some psychological benefits. Conclusions: These findings underline the need to continue the develop cancer patients’ service that can provide quality, improve hospital stay and quality of life of patients and their familiars. No significant financial relationships to disclose.